Nivolumab plus chemotherapy in metastatic gastric cancer with low combined positive score.

ABSTRACT:

Background

A combination of immune checkpoint inhibitors and chemotherapy has emerged as standard therapy in advanced human epidermal growth factor receptor 2-negative advanced gastric cancer (AGC). However, the clinical benefit in patients with a low combined positive score (CPS) of 1-4 remains controversial.

Objectives

To evaluate the efficacy and safety of nivolumab plus chemotherapy in AGC patients with low CPS (1-4) in a real-world clinical setting.

Design

A retrospective single-center study conducted at Samsung Medical Center.

Methods

We analyzed outcomes in AGC patients with CPS 1-4 who received nivolumab in combination with capecitabine and oxaliplatin (XELOX) or fluorouracil, oxaliplatin, and leucovorin (FOLFOX) as first-line therapy between April 2021

SUBMITTER: Kim J 

PROVIDER: S-EPMC12665014 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature